60. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2011;25(5):553-559. 61. Wooldridge JE, Anderson CM, Perry MC. Corticosteroids in advanced cancer. Oncology (Williston Park). 2001;15(2):225-234; discussion 234-226. 62. Fleming JA, O’Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag. 2009;14(5):381-388. 63. Ferrini R, Paice JA. How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. J Support Oncol. 2004;2(1):90-94. 64. Carter GT, Flanagan AM, Earleywine M, Abrams DI, Aggarwal SK, Grinspoon L. Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Am J Hosp Palliat Care. 2011;28(5):297-303. 65. Aggarwal SK, Kyashna-Tocha M, Carter GT. Dosing medical marijuana: rational guidelines on trial in Washington State. MedGenMed. 2007;9(3):52. 66. Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther. 2008;327(2):584-591. 67. Ashton JC, Milligan ED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Investig Drugs. 2008;9(1):65-75. 68. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90(6):844-851. 69. Corbin LW, Mellis BK, Beaty BL, Kutner JS. The use of complementary and alternative medicine therapies by patients with advanced cancer and pain in a hospice setting: a multicentered, descriptive study. J Palliat Med. 2009;12(1):7-8. 70. Bercovitz A, Sengupta M, Jones A, Harris-Kojetin LD. Complementary and alternative therapies in hopsice: the national home and hospice care survey: United States, 2007. Hyattsville, MD: National Center for Health Statistics;2010. 71. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia; a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9(4):361-381. 72. Ayalon L, Gum AM, Feliciano L, Arean PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med. 2006;166(20):2182-2188. 73. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51(9):1305-1317. 74. O’Connor DW, Ames D, Gardner B, King M. Psychosocial treatments of behavior symptoms in dementia: a systematic review of reports meeting quality standards. International psychogeriatrics / IPA. 2009;21(2):225-240. 75. Ueda T, Suzukamo Y, Sato M, Izumi S. Effects of music therapy on behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. Ageing Res Rev. 2013;12(2):628- 641. 76. Scales K, Zimmerman S, Miller SJ. Evidence- Based Nonpharmacological Practices to Address Behavioral and Psychological Symptoms of Dementia. The Gerontologist. 2018;58(suppl_1):S88-S102.
77. Fung JK, Tsang HW, Chung RC. A systematic review of the use of aromatherapy in treatment of behavioral problems in dementia. Geriatr Gerontol Int. 2012;12(3):372-382. 78. Thodberg K, Sorensen LU, Christensen JW, et al. Therapeutic effects of dog visits in nursing homes for the elderly. Psychogeriatrics. 2016;16(5):289- 297. 79. Kutner JS, Smith MC, Corbin L, et al. Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann Intern Med. 2008;149(6):369-379. 80. Keefe FJ, Abernethy AP, L CC. Psychological approaches to understanding and treating disease- related pain. Annu Rev Psychol. 2005;56:601-630. 81. Cassileth BR, Keefe FJ. Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. Oncologist. 2010;15 Suppl 2:19- 23. 82. Weitzen S, Teno JM, Fennell M, Mor V. Factors associated with site of death: a national study of where people die. Med Care. 2003;41(2):323-335. 83. Angus DC, Barnato AE, Linde-Zwirble WT, et al. Use of intensive care at the end of life in the United States: an epidemiologic study. Crit Care Med. 2004;32(3):638-643. 84. Mularski RA, Puntillo K, Varkey B, et al. Pain management within the palliative and end-of-life care experience in the ICU. Chest. 2009;135(5):1360- 1369. 85. Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. Crit Care Med. 2001;29(12):2258- 2263. 86. Gelinas C, Fillion L, Puntillo KA, Viens C, Fortier M. Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006;15(4):420- 427. 87. Puntillo KA, Morris AB, Thompson CL, Stanik-Hutt J, White CA, Wild LR. Pain behaviors observed during six common procedures: results from Thunder Project II. Crit Care Med. 2004;32(2):421-427. 88. Desbiens NA, Mueller-Rizner N. How well do surrogates assess the pain of seriously ill patients? Crit Care Med. 2000;28(5):1347-1352. 89. Markowitz AJ, Rabow MW. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time . . . nothing was working”. JAMA. 2008;299(15):1826. 90. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000(2):CD001219. 91. Campbell ML, Templin T, Walch J. A Respiratory Distress Observation Scale for patients unable to self-report dyspnea. J Palliat Med. 2010;13(3):285- 290. 92. Portenoy RK, Sibirceva U, Smout R, et al. Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manage. 2006;32(6):532-540. 93. Battin MP. Terminal sedation: pulling the sheet over our eyes. Hastings Cent Rep. 2008;38(5):27-30. 94. Peppin JF. Intractable symptoms and palliative sedation at the end of life. Christ Bioeth. 2003;9(2- 3):343-355. 95. Avorn J, Shrank WH. Adverse Drug Reactions in Elderly People: A substantial cause of preventable illness. BMJ. 2008;336(7650):956-957. 96. Billings JA. The end-of-life family meeting in intensive care part I: Indications, outcomes, and family needs. J Palliat Med. 2011;14(9):1042-1050.
97. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry.169(9):946-953. 98. Rabins PV, Blacker D, Rovner BW, et al. American Psychiatric Association practice guidelines: treatment of patient’s with Alzheimer’s disease and other dementias. psychiatryonline 2007; DOI: 10.1176/appi.books.9780890423967.152139. 2007. 99. Hersch E, Falzgraf S. Management of the behavioral and psychological symptoms of dementia. Clinical interventions in aging. 2007;2(4):611-621. 100. 100. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169. 101. Burrett-Jerrott SE SS. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8:45-58. 102. Meehan KM WH, David SR, et al. . Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26(4):494-504. 103. US Administration. Information for Healthcare Professionals: Antipsychotics. Available at:http://www.fda. gov/Drugs/DrugS afety/cPostmarketDrugSafe tyInformationforPatientsandProviders/ ucm124830.htm. 2008. 104. Hospice & Palliative Nurses Association. Final Days: Patient/Family Teaching Sheet. 2012. 105. Beauchamp TL, Childress JF. Principles of biomedical ethics, 5th Ed. Oxford, UK: Oxford University Press; 2001. 106. Edwards MJ. Opioids and benzodiazepines appear paradoxically to delay inevitable death after ventilator withdrawal. J Palliat Care. 2005;21(4):299-302. 107. Bruce A, Boston P. Relieving existential suffering through palliative sedation: discussion of an uneasy practice. J Adv Nurs. 2011;67(12):2732-2740. 108. Verkerk M, van Wijlick E, Legemaate J, de Graeff A. A national guideline for palliative sedation in the Netherlands. J Pain Symptom Manage. 2007;34(6):666-670. 109. 109. Hickman SE, Keevern E, Hammes BJ. Use of the physician orders for life-sustaining treatment program in the clinical setting: a systematic review of the literature. J Am Geriatr Soc. 2015 Feb;63(2):341-50. doi: 10.1111/jgs.13248. Epub 2015 Jan 29. PMID: 25644280. 110. Treede, R. D. (2018). The International Association Food and Drug for the Study of Pain definition of pain: As valid in 2018 as in 1979, but in need of regularly updated footnotes. Pain Reports, 3(2), e643. https://doi. org/10.1097/PR9.0000000000000643 111. DiPiro, J., Yee, G., Posey, L. M., Haines, S. T., Nolin, T. D., & Ellingrod, V. (2019). Pharmacotherapy: A pathophysiologic approach (8th ed.) McGraw-Hill. 112. Barbee, J., Russell, C., Cotton, J., & Fleischfresser, J. (2017). Breaking through breakthrough cancer pain. Pharmacy Times. Retrieved September 22, 2022 from https://www.pharmacytimes.com/view/ breaking-through-breakthrough-cancer-pain 113. Treede, R. D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N. B., First, M. B., Giamberardino, M. A., Kaasa, S., Kosek, E., Lavand’homme, P., Nicholas, M., Perrot, S., Scholz, J., Schug, S., Smith, B. H., Svensson, P., … Wang, S. J. (2015). A classification of chronic pain for ICD-11. Pain, 156(6), 1003–1007. https:// doi.org/10.1097/j.pain.0000000000000160
41
Powered by FlippingBook